The expression of the cytochrome P450 CYP3A5 enzymes shows a wide variation across the general population and ethnic groups. This wide disparity implies interracial differences in drug clearance and susceptibility to diseases such as cancer. CYP3A5 polymorphisms were rapidly determined using polymerase chain reaction-restriction fragment length polymorphism analysis in 113 Taiwanese patients with hepatoma, 70 with cervical cancer, 92 with breast cancer, 82 with oral cancer, 90 with thyroid cancer, 133 with lung cancer, and 270 healthy controls. The allelic frequencies of CYP3A5*1 were 25% in hepatoma patients, 33% in cervical cancer patients, 31% in breast cancer patients, 22% in oral cancer patients, 23% in thyroid cancer patients, 20% in lung cancer patients, and 27% in healthy subjects. Lung cancer patients had a significantly lower frequency (20%) of CYP3A5*1 expression than healthy controls (p = 0.028, odds ratio = 1.49, 95% confidence interval = 1.04-2.13), but there was no statistically significant difference between healthy controls and other cancers. We suggest that CYP3A5*1 may play an important role in individual predisposition to lung cancer in Taiwan.
The CYP3A enzymes represent most of the cytochrome P450 (CYP) activity in the liver and lung [1, 2] . In addition to other functions, CYP3A catalyzes the oxidation of xenobiotics, including carcinogens, toxins, and drugs [3] . This specific reaction converts a procarcinogen to its carcinogen form or deactivates about half of drugs currently in clinical use [3] [4] [5] . Four members of the human CYP3A subfamily, CYP3A4, CYP3A5, CYP3A7, and CYP3A43, have been identified and their expressions are differentially regulated. CYP3A5 is found in adult tissues and represents most of the CYP3A activity in lung.
Two linked mutations in the promoter region of the CYP3AP1 gene, A/G (-44) and T/G (-369), are associated with CYP3A5 expression and activity [4, 6] . Kuehl et al reported a direct concordance between the A/G (-44) polymorphism of CYP3AP1 and the CYP3A5*1 allele in Caucasians [7] . The polymorphic CYP3AP1*1 was in positive linkage with the polymorphic CYP3A5*1 allele, and subjects with A/G (-44) in CYP3AP1 also carried at least one CYP3A5*1 allele. Although CYP3A5 expression is closely correlated with the CYP3AP1*1 genotype, the expression was better predicted by CYP3A5 genotype [7] . This obser-vation enables correlation of CYP3A5*1 polymorphism with CYP3A5 expression.
Inter-individual variation in CYP3A5 activity could influence individual predisposition to cancers caused by environmental carcinogens or endogenous substances, such as aflatoxin B1 for liver cancer and estrogen for breast cancer. Numerous carcinogens and chemicals are enzymatically activated to their ultimate carcinogenic form by CYP3A5. These enzymes can also inactivate toxic substances and some carcinogens by similar reactions. An individual's risk of lung cancer increases more than 5-fold if at least one parent has lung cancer [8] , implying a role for genetic factors in susceptibility to this cancer. In this study, we investigated CYP3A5 polymorphisms in several cancers to explore the relationship among them.
MATERIALS AND METHODS
Blood samples (2 mL) were collected from 270 normal individuals, 113 hepatoma patients, 70 cervical squamous cell carcinoma patients, 92 breast intraductal carcinoma patients, 133 lung squamous cell carcinoma patients, 82 oral squamous cell carcinoma patients, and 90 thyroid papillary adenocarcinoma patients. All were Taiwanese. Total genomic DNA was then isolated from peripheral leukocytes as described previously [9] . This study was approved by the institutional review boards of the Chinese Medical College Hospital and the Changhua Christian Hospital.
PCR-RFLP analysis
Polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) assays were used to find A to G mutations at nucleotide (nt) 22,893 (GeneBank AC005020) in individual samples. A Dde I restriction enzyme site containing nt 22,893 was created using an oligonucleotide mismatch (underlined base) in the upstream PCR primer. An exogenous restriction site was created by the PCR reaction in CYP3A5*3 alleles, with a guanine (G) at nt 22,892. There was no such site in CYP3A5*1 alleles, where there was an adenine (A) at nt 22,892. The sequences of the primer pair for the C Y P 3 A 5 * 1 / C Y P 3 A 5 * 3 a l l e l e s w e r e 5 ' -
C T C T T T A A A G A G C T C T T T T G T C T C T C A -3 '
(upstream, from nt 22,866 to nt 22,892 in AC005020) a n d 5 ' -G T T G T A C G A C A C A C A G C A A C C -3 ' (downstream, from nt 23,000 to nt 23,020 in AC005020), potentially giving a 6-base-pair (bp) Dde I enzyme site containing nt 22,893 (AC005020).
All samples used to determine CYP3A5*3 and CYP3A5*1 genotypes were also used to determine CYP3A5*6 genotypes. The sequences of the primer pair used to determine CYP3A5*6 genotype were 5'-GATAGTTCTGAAAGTCTGTGGC-3' (upstream, from nt 30,371 to nt 30,392 in AC005020) and 5'-G A G A G A A A T A A T G G A T C T A A G A A A C C -3 ' (downstream, from nt 30,613 to nt 30,638 in AC005020), abolishing the endogenous Dde I enzyme site containing nt 30,597 (AC005020) in CYP3A5*6 alleles.
Each PCR was carried out in 50 L of reaction mixture containing 200 ng genomic DNA, 1x Taq buffer, 0.2 mM of dNTP, 0.2 M of each primer, and 0.4 U Taq polymerase (Protech, Taipei, Taiwan). The following conditions were used in each cycle: 94 C for 1 minute, annealing temperature for 1 minute, and 72 C for 90 seconds. The annealing temperature was 58 C for CYP3A5*3 and 60 C for CYP3A5*6 primer pairs. Primerdirected amplification was repeated for 35 cycles.
After PCR amplification, the DNA fragments were digested with Dde I at 37 C for 4 hours before electrophoresis on a 3.5% agarose gel in 0.5x TAE (Tris-acetate-EDTA) buffer. PCR products were distinguished by the size of the main fragments on electrophoresis. There is an endogenous Dde I site 20 bp from the 3' end of the amplified CYP3A5*3 product in the CYP3A5*3/CYP3A5*1 assay, so three fragments (20, 110, and 25 bp) are released by Dde I digestion of the 155 bp fragment from a patient homozygous for CYP3A5*3. In the CYP3A5*1 allele, only two fragments (130 and 25 bp) are released because no new Dde I recognition site is created (Figure 1, lanes 1 and 2) . The PCR-amplified product of the CYP3A5*6 reaction (168 bp) is digested into three fragments (120, 128, and 20 bp) for CYP3A5*6 alleles or four fragments (120, 103, 25, and 20 bp) for CYP3A5*1 alleles (Figure 2, lanes 1  and 2) .
Sequencing analysis of amplified fragments
PCR-amplified products were purified using a PCR purification kit (QIAquick, Qiagen Inc., Valencia, CA, USA). PCR products containing polymorphic CYP3A5*1/*1, CYP3A5*1/*3, or CYP3A5*3/*3 alleles were then subjected to direct sequencing using an ABI PRISM 310 Genetic Analyzer (Applied Biosystems, San Francisco, CA, USA). The PCR primers were also used for sequencing.
Statistical analysis
The differences in distribution of CYP3A5 genotypes between tumor patients and healthy controls were determined by the Chi-squared test.
Probability values of less than 0.05 were regarded as statistically significant. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using unconditional logistic regression and adjusted for age and gender to estimate the association between certain genotypes and diseases. All statistical analyses were performed using the Statistical Analysis System software, version 6.12 (SAS Institute, Cary, NC, USA).
RESULTS

Polymorphisms at nt 22,893 for CYP3A5*3
The expected 110 bp fragment of the CYP3A5*3 allele was visible on 3.5% agarose gel, whereas the 20 and 25 bp fragments were indistinguishable and less intense on the gel (Figure 1, lanes 5 and 6) . The expected 130 bp fragment for the CYP3A5*1 allele was distinguishable from the CYP3A5*3 110 bp fragment and the uncut 155 bp band on the gel (Figure 1 ). Four fragments were expected in the PCR products of heterozygous (CYP3A5*1/*3) subjects. However, only the longer fragments (110 and 135 bp) were observed; the shorter fragments (35 and two copies of 20 bp) were retarded at a similar distance on the gels (Figure 1, lanes 3 and 4) .
The CYP3A5 allelic frequencies and genotypes for the 580 patients and 270 controls are shown in Tables  1 and 2 . There was a significantly lower frequency of CYP3A5*1 polymorphism in patients with lung cancer (p = 0.028, OR = 1.49, 95%CI = 1.04-2.13) than in normal controls, but there was no difference between normal controls and other cancers.
Frequencies of CYP3A5*1 are similar among male and female lung cancer patients
Of the lung cancer patients, 105 were male and 28 were female, giving an incidence ratio of nearly 4 to 1. Frequencies of the CYP3A5*1 allele were 20% and 18% in males and females, respectively ( Table 3 ). The smoking histories of these patients were further analyzed: there were 96 male smokers or ex-smokers, but there were no smokers among the women. The allelic frequencies of CYP3A5*1 in male smokers and non-smokers were 22% and 5.6%, respectively, and the incidence ratios of carrying at least one CYP3A5*1 allele were 35% and 11%, respectively. For normal controls, the incidence ratio of carrying at least one CYP3A5*1 allele was 48% (Table 2) .
Frequencies of polymorphisms at nt 30,597 for CYP3A5*6
No CYP3A5*6 allele was identified in the tested samples. We sequenced the PCR products from some of the samples to accurately confirm these results. 
DISCUSSION
CYP3A5 polymorphisms influence CYP3A5 activity [7] . People with at least one CYP3A5*1 allele have relatively high levels of CYP3A5 expression in their liver and intestines. The number of copies of polymorphic CYP3A5*3 and CYP3A5*6 alleles in a person directly affects CYP3A5 expression. There are considerable interracial and inter-individual differences in CYP3A5 activity. The results of this study are the first to show that no CYP3A5*6 allele was present in Taiwanese. This finding further demonstrates that CYP3A5*6 is rare not only in Caucasians and African Americans but also in Taiwanese. Among Taiwanese, the allelic frequency of CYP3A5*1 is approximately 27%, with 48% of normal subjects bearing at least one CYP3A5*1 allele. These individuals are predicted to express relatively high amounts of CYP3A5 enzymes. Consequently, they are more likely to clear drugs that are inactivated by CYP3A5 more efficiently and have different risks of diseases associated with CYP3A5 expression.
CYP enzymes are the primary enzymes that catalyze procarcinogens to carcinogens. For instance, CYP3A5 
